Ptc Therapeutics PTCT Institutional Ownership

Updated Oct 11, 2026

Ptc Therapeutics, Inc. (NASDAQ:PTCT) appeared in the 13F filings of 381 institutional investors for the quarter ended June 30, 2026.

• Total shares held in Ptc Therapeutics rose 4.96% versus Q1 2026, while the number of holders rose 35.11% versus Q2 2025.
• Among the 381 holders of Ptc Therapeutics, 218 added to their positions, 111 reduced their stakes and 52 left their positions unchanged.
• The aggregate institutional position in Ptc Therapeutics was 100.27Mn shares at the end of Q2 2026, up 4.74Mn from the prior quarter and up 22.43Mn from a year earlier.
• BlackRock, Inc. was the top holder of Ptc Therapeutics as of June 30, 2026, with 13.96Mn shares.
• Among existing holders, the largest additions to Ptc Therapeutics in Q2 2026 came from BlackRock, Inc. (+1.02Mn shares), Blue Sparrow, LLC (+860.1K shares), T. Rowe Price Associates Inc (+639.37K shares), Arrowstreet Capital, Limited Partnership (+542.75K shares) and American Century Companies Inc (+495.99K shares).
• The biggest cuts to PTCT positions during Q2 2026 came from UBS Group AG (-1.1Mn shares), Armistice Capital, LLC (-1Mn shares), Toronto Dominion Bank (-860.12K shares), BNP Paribas Financial Markets (-541.76K shares) and Balyasny Asset Management L.P. (-439.96K shares).
• According to Business Quant data, the leading holders of PTCT for Q2 2026 were BlackRock, Inc. (13.96Mn shares), RTW Investments, LP (7.75Mn shares), Jupiter Topco LLC (7.24Mn shares), Vanguard Portfolio Management LLC (4.93Mn shares), State Street Corp (4.6Mn shares), Wellington Management Group LLP (4.13Mn shares), Vanguard Capital Management LLC (3.74Mn shares), Geode Capital Management, LLC (2.21Mn shares), Toronto Dominion Bank (2.17Mn shares) and Westfield Capital Management Co LP (1.96Mn shares).